Ibedenona

Idebenone (known under the trade names Catena and Sovrima) is an experimental drug, initially developed by the company Santhera Pharmaceuticals for the treatment of Alzheimer's disease and other cognitive impairments. This has had limited success. The Swiss company Santhera Pharmaceuticals has begun to investigate its use for the treatment of neuromuscular diseases. In May 2010, the first clinical trials for the treatment of Friedreich's ataxia and Duchenne muscular dystrophy were completed. Chemically, idebenone is an organic compound of the benzoquinone family. It is also marketed as a synthetic analogue of coenzyme Q10. There have also been trials that have proven their effects as a potent antioxidant. Nootropic effects and Alzheimer's disease

Idebenone improves learning and memory in mice experiments. In humans, endpoint criteria, such as electroretinogram tests, and scales of evocative potential and analogue visual scales, have also been suggested to have positive nootropic effects, but more extensive studies with endpoint criteria have been discontinued. / p> Research on idebenone as a potential therapy for Alzheimer's disease has been inconsistent, but there may be a tendency for a slight benefit. In May 1998, approval for this indication was canceled in Japan due to lack of proven effects. In some European countries, the drug is available for the treatment of specific patients in special cases.

wiki